A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Irinotecan (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 03 Dec 2019 Planned End Date changed from 30 Jun 2021 to 30 Sep 2021.
- 03 Dec 2019 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2021.
- 07 Sep 2018 Planned End Date changed from 31 Oct 2020 to 30 Jun 2021.